2020
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino K, Park T, Ahuja N. Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars In Cancer Biology 2020, 65: 114-122. PMID: 31911188, DOI: 10.1016/j.semcancer.2020.01.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsResponse ratePeripheral T-cell lymphomaTriple-negative breast cancerLarge B-cell lymphomaDurable response rateEffective standard therapyDeath protein 1Solid organ tumorsInhibitory immune receptorsT-cell lymphomaNegative breast cancerB-cell lymphomaAdvanced malignanciesMost patientsStandard therapyClinical efficacyCommon malignancyHepatobiliary cancersTherapeutic optionsNeck cancerOrgan tumorsInitial respondersOvarian cancerProstate cancerBreast cancer
2017
Differential expression of hENT1 and hENT2 in colon cancer cell lines
Liu Y, Zuo T, Zhu X, Ahuja N, Fu T. Differential expression of hENT1 and hENT2 in colon cancer cell lines. Genetics And Molecular Research 2017, 16 PMID: 28218790, DOI: 10.4238/gmr16019549.Peer-Reviewed Original ResearchConceptsColon cancer cell linesCancer cell linesMetastatic CRCColorectal cancerHENT1 expressionCell linesHigh hENT1 expressionLow hENT1 expressionMetastatic colorectal cancerNucleoside analoguesHuman equilibrative nucleoside transporter 1Equilibrative nucleoside transporter 1Real-time polymerase chain reactionDrug-based treatmentQuantitative real-time polymerase chain reactionHuman colon cancer cell linesNucleoside transporter 1Clinical responseMost patientsMetastatic cell linesMetastatic sitesMetastatic tumorsTransporter expression profilesPolymerase chain reactionDifferent drug responses
2016
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Research 2016, 76: 1683-1689. PMID: 26988985, PMCID: PMC4873370, DOI: 10.1158/0008-5472.can-15-2125.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor efficacyCheckpoint inhibitor efficacyImmune checkpoint blockadeCurrent clinical trialsT-cell attractionException of melanomaAdvanced human cancersCancer management strategiesEpithelial cancer cellsCheckpoint blockadeMost patientsCombination therapyCancer testisClinical trialsDNA methyltransferase inhibitorMouse modelInhibitor efficacyImmune signalingCancer cellsHuman cancersMethyltransferase inhibitorEpigenetic drugsDemethylating agentExciting recent advancesEndogenous retroviruses
2015
Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience
Ball MW, Sundi D, Reese AC, Meyer CF, Terezakis SA, Efron JE, Schoenberg MP, Epstein JI, Ahuja N, Bivalacqua TJ. Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer 2015, 13: 435-440. PMID: 26003268, DOI: 10.1016/j.clgc.2015.04.011.Peer-Reviewed Original ResearchConceptsCancer-specific survivalRecurrence-free survivalProstate sarcomaOverall survivalSurgical resectionLocal recurrenceMedian recurrence-free survivalFavorable cancer-specific survivalCommon presenting symptomRecords of patientsPatient demographic informationJohns Hopkins ExperienceActuarial OSConcurrent chemotherapyCurative intentMedian OSNeoadjuvant chemoradiationNeoadjuvant radiationOncological outcomesPresenting symptomMost patientsRFS ratesUrinary obstructionMetastatic recurrenceTumor characteristics
2012
Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG, Gamblin TC, Pawlik TM. Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients. Annals Of Surgical Oncology 2012, 19: 4036-4042. PMID: 22972507, PMCID: PMC3568525, DOI: 10.1245/s10434-012-2634-6.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalDesmoid tumorsTumor locationWorse recurrence-free survivalRare soft tissue neoplasmMajor surgical centersR0 surgical marginsDisease-free survivalEffective adjuvant therapyManagement of patientsPredictors of recurrenceRate of recurrenceMulti-institutional analysisSoft tissue neoplasmBackgroundDesmoid tumorsResultsMedian ageAdjuvant therapyMost patientsSurgical resectionMargin statusSurgical marginsSurgical centersTreatment characteristicsRecurrence patternsAbdominal cavityEpithelioid sarcoma: one institution's experience with a rare sarcoma
Guzzetta AA, Montgomery EA, Lyu H, Hooker CM, Meyer CF, Loeb DM, Frassica D, Weber KL, Ahuja N. Epithelioid sarcoma: one institution's experience with a rare sarcoma. Journal Of Surgical Research 2012, 177: 116-122. PMID: 22575361, PMCID: PMC3715113, DOI: 10.1016/j.jss.2012.04.030.Peer-Reviewed Original ResearchConceptsEpithelioid sarcomaOverall survivalDiagnosis of ESRegional lymph node metastasisRare soft tissue sarcomaAvailable histological slidesCentralized cancer registryMedian overall survivalNumber of resectionsInstitutional review board approvalRegional nodal basinLymph node metastasisSoft tissue sarcomasNumber of recurrencesMajority of tumorsReview board approvalJohns Hopkins Medical InstitutionsRepeated ResectionMedian ageMost patientsMedian timeNode metastasisPatient chartsCancer RegistryInstitution experience
2009
Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series
Reddy S, Cameron JL, Scudiere J, Hruban RH, Fishman EK, Ahuja N, Pawlik TM, Edil BH, Schulick RD, Wolfgang CL. Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series. Journal Of The American College Of Surgeons 2009, 208: 950-957. PMID: 19476869, PMCID: PMC3109868, DOI: 10.1016/j.jamcollsurg.2009.01.044.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary neoplasmMalignant potentialFormal surgical resectionMedian tumor sizeOutcomes of patientsLymph node metastasisRare pancreatic tumorR1 resectionAbdominal painR0 resectionR2 resectionInstitutional seriesMost patientsSurgical resectionUnrelated causesClinicopathologic characteristicsComplete resectionMedian ageNode metastasisDistant metastasisPerineural invasionSurgical managementCommon symptomsLongterm outcomesTumor size
2005
Long‐Term Function After Restorative Proctocolectomy
Wheeler JM, Banerjee A, Ahuja N, Jewell DP, Mortensen NJ. Long‐Term Function After Restorative Proctocolectomy. Diseases Of The Colon & Rectum 2005, 48: 946-951. PMID: 15868242, DOI: 10.1007/s10350-004-0885-4.Peer-Reviewed Original ResearchConceptsIleoanal pouch surgeryLong-term functional outcomePercent of patientsFunctional outcomePouch surgeryRestorative proctocolectomyIleoanal pouchExcellent long-term optionEarly functional outcomesLong-term functionMost patientsPouch failureConsecutive patientsMedian agePerfect continencePatientsProctocolectomyStandardized questionnaireSurgeryOutcomesPouchMinimal dataMonthsTotalQuestionnaire